01 Jul 12:00 Business FierceBiotech Argenx signs $1.5B pact to turn Unnatural Products' macrocyclic peptides to 'undruggable' targets
30 Jun 13:45 Business FierceBiotech AbbVie reels in Capstan in $2.1B buyout, charting course for in vivo CAR-T market
20 Jun 05:53 Business FierceBiotech Industry deeply disappointed as FDA reportedly puts cell and gene therapy chief on leave
13 Jun 17:22 Business FierceBiotech J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients
12 Jun 12:17 Business FierceBiotech BioNTech buys German mRNA vaccine peer CureVac in $1.2B all-stock deal
